Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Prestige Consumer Healthcare (PBH)

Prestige Consumer Healthcare Q2 revenue down 0.9% to $283.8 million; EPS up to $1.09

Mixed Impact 3 of 5 earnings Written later

Prestige Consumer Healthcare reported fiscal second-quarter 2025 results for the three months ended September 30, 2024. Revenue fell 0.9% to $283.8 million, which the company attributed mainly to limited ability to supply strong demand for Clear Eyes and declines in the Cough & Cold and Analgesic categories, while diluted EPS rose to $1.09 from $1.07 and the company reaffirmed its full-year fiscal 2025 outlook. For shareholders, lower revenue was paired with slightly higher per-share earnings and unchanged guidance.

Key points

  • Q2 revenue of $283.8 million, down 0.9% from $286.3 million a year earlier
  • Q2 diluted EPS of $1.09 vs. $1.07; net income of $54.4 million vs. $53.6 million
  • First-half revenue of $550.9 million, down 2.6%; first-half diluted EPS of $2.06 (non-GAAP adjusted $1.98)
  • Fiscal 2025 outlook reaffirmed: revenue of $1,125 to $1,140 million and adjusted diluted EPS of $4.40 to $4.46

The filing

CompanyPrestige Consumer Healthcare (PBH)
Form8-K, current report
Filed with the SECNov 7, 2024, 6:03 AM ET
Accession number0001295947-24-000030

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 07, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.